Compared with manual SICS, temporal-side incision in phacoemulsification decreased corneal sensitivity in the incision site and other sites until day 15 and changes in tear film quantity and patient symptoms only on day 1.
Background: Vancomycin and ceftazidime are commonly used intravitreal antibiotics to treat acute post-phacoemulsification endophthalmitis. However, they are not commercially available in appropriate therapeutic dose for intravitreal injection. Moxifloxacin is a broad-spectrum antibiotic that is commercially available in appropriate therapeutic dose for intravitreal injection, thus providing a rationale for its use in acute post-phacoemulsification endophthalmitis.Case presentation: A 46-year-old female presented with blurred vision, redness, and pain in the right eye 5 days after phacoemulsification. Visual acuity was hand movement and conjunctival and circumcorneal injection, corneal oedema, anterior chamber reaction, and vitreous opacities were observed. The patient was treated with intravitreal moxifloxacin 500 μg/0.1 ml, vitrectomy, and topical and oral antibiotics. Visual acuity improved to 6/15 and follow-up at 5 weeks did not reveal any signs of intraocular inflammation.Conclusion: Intravitreal moxifloxacin is an alternative in the treatment of acute post-phacoemulsification endophthalmitis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.